Top View
- And Thiourea-Containing Sorafenib Analogs As EGFR and VEGFR-2 Dual TK Inhibitors
- ATC/DDD Classification (Final)
- Re-Biopsy Status Among Chinese Non-Small-Cell Lung Cancer Patients Who Progressed After Icotinib Therapy
- Fatal Interstitial Lung Disease Associated with Icotinib
- Integrin Α5 Promotes Migration and Invasion Through the FAK/STAT3/AKT Signaling Pathway in Icotinib‑Resistant Non‑Small Cell Lung Cancer Cells
- Original Article Phase I Study of Icotinib, an EGFR Tyrosine Kinase Inhibitor Combined with IMRT in Nasopharyngeal Carcinoma
- Anlotinib: a Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development
- Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
- Supplementary Appendix
- Efficacy and Safety of First Line Treatments for Patients with BMJ: First Published As 10.1136/Bmj.L5460 on 7 October 2019
- Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
- The Proto-Oncogene C-Kit Inhibits Tumor Growth by Behaving As a Dependence Receptor Hong Wang
- Effect of Icotinib on Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation Detected in Ctdna by Ddpcr
- Investigational Drug: Sintilimab (IBI308) Innovent Biologics (Suzhou) Co., Ltd
- Crizotinib with Or Without an EGFR-TKI in Treating EGFR-Mutant
- New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome Leah J
- Efficacy and Safety of Icotinib in Patients with Brain Metastases from Lung Adenocarcinoma
- 2016 Full Year Results
- A Comparison Between First-, Second- and Third-Generation Epidermal
- A Positive Feedback Loop Formed by NGFR and FOXP3 Contributes to the Resistance of Non-Small Cell Lung Cancer to Icotinib
- Changelog (In Alphabetical Order of the Value Set) Value Set Code Description Change
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- In Vitro and Ex Vivo Anti‑Tumor Effect and Mechanism of Tucatinib in Leukemia Stem Cells and ABCG2‑Overexpressing Leukemia Cells
- Lung Cancer: a Meta-Analysis
- Qualifying Therapeutic Discovery Project Grants
- Methods of Administering an Egfr Inhibitor Verfahren Zur Verabreichung Eines Egfr-Hemmers Methodes D’Administration Un Inhibiteur D’Egfr
- Retrospective Study of Adjuvant Icotinib in Postoperative Lung
- Eunethta Joint Action 3 WP4 ALECTINIB AS MONOTHERAPY
- Remission of Psoriasis During Treatment with Apatinib in a Patient
- Routine-Dose and High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients Harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial
- Advances in Targeted Therapy for Esophageal Cancer
- Combining Radiation Therapy with Systemic Targeted Therapies in Intracranial Metastatic Disease Michael J
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Tyrosine Kinase Inhibitors Enhanced the Efficacy of Conventional Chemotherapeutic Agent in Multidrug Resistant Cancer Cells Shaocong Wu and Liwu Fu*
- Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases
- NF1 Clinical Pipeline: Active Interventional Drug Therapies
- Case Report Tumor Heterogeneity with Novel MET Fusion Showed Different Response to Cabozantinib in Non-Small Cell Lung Cancer
- Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Invasion
- January 28-31, 2021 | Worldwide Virtual Event Connect with Us
- Original Article Identification of a Novel Crizotinib-Sensitive NR-110219
- New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome Leah J
- Radiation Therapy for Brain Metastases
- Adjuvant EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Still an Investigational Approach
- Tyrosine Kinase Receptors in Oncology
- Imatinib-Induced Ophthalmological Side-Effects in GIST Patients Are Associated with the Variations of EGFR, SLC22A1, SLC22A5 and ABCB1